However,lack of further in-depth invetigations of underlying molecular signalingpathways, in vivo efficacy of AGL in LA7 cell-transplantedsyngeneic tumor model, and detailed systemic toxicity profile inanimal models are limitations of the current study, which are necessarybefore making any effort for translating AGL as a potential agentfor breast cancer therapy. The gene discussed is AGL; the disease is breast cancer.